I
n the editorial by Devlin et al (1) on our publication evaluating the association of corticosteroids with transitioning from a "normal" (i.e., noncomatose and nondelirious) state to a delirious state (2), they noted our exclusion of the competing transitions to coma, ICU discharge, and death, raising the question of "overestimation of the risk for delirium associated with corticosteroid administration" (1) .
To address this question, we used a first-order Markov model (3) to estimate the probability of transitioning from a normal, delirious, or comatose state on a given day to one of the following five states on the next day: normal, delirious, comatose, ICU discharge, or death. This model included all consecutive days with delirium or coma assessments and was fit using a multinomial logistic regression model with robust variance estimates that included the 12 exposure variables in our original multivariable analysis (2). We allowed the association of corticosteroids (and other exposure variables) with transition to a delirious state to vary based on the subject's prior state (normal vs comatose) using statistical interaction terms.
In our original analysis (2), estimating the probability of transitioning from a normal state to a delirious state (reported as 14%) (2) was not the primary goal, instead our focus was on the association of corticosteroids with this transition. When analyzing the data to consider all possible states, as suggested by Devlin et al (1) , this probability was modestly lower at 11% (see bolded value in Table 1 ). The complete set of transition probabilities (Table 1 ) also demonstrates the high probability of delirium when transitioning out of a comatose state. Of 2,397 days in which a patient was comatose on the prior day, in 1,865 days (78%) patients remained comatose and in 106 (4%) they transitioned to death. In the remaining 426 days where survivors transitioned out of coma, 389 (91%) transitioned to delirium, with only 30 (7%) transitioning to a normal state and seven (2%) being discharged from ICU.
In Table 2 , we report our original results (2) versus results from the expanded statistical analysis as previously described. The primary exposure variable, systematic corticosteroids administered on the prior day, was significantly associated with transition to delirium with an odds ratio (95% CI) of 1.46 (1.02-2.11; p = 0.04) that was very similar to the originally reported value of 1.52 (1.05-2.21; p = 0.03) (2). Therefore, the similar estimate produced by the expanded model, accounting for all states, suggests that the original results did not overestimate the association of corticosteroids with the transition from a normal to a delirious state.
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Dr. Colantuoni's institution received grant support from the National Institutes of Health (NIH). Dr. Neufeld's institution received grant support from Ornim Medical Device. Dr. Needham received support for article research from the NIH. His institution received grant support from the NIH,W e thank Wozniak et al (1) for responding to the concern we raised in our editorial (2) that accompanied their excellent analysis of corticosteroid exposure to delirium transition in critically ill adults with acute lung injury (ALI) (3). By incorporating the competing transitions of coma, ICU discharge and death, to their first-order Markov model, all possible daily transitions in patients mental status are now considered, and the results of this new model is more consistent with the actual transitions of patients admitted with ALI through their ICU admission.
The fact that the reported estimates of their expanded model were nearly identical to those originally reported is not surprising given that a multinomial logistic regression analysis was used and thus odds ratios (ORs) are reported. In multinomial models, adding or deleting alternative outcome categories will not materially affect the ORs reported among the remaining outcomes. When evaluating the effects of therapies in the ICU that can result in serious, yet common, harmful outcomes 
